drugset / Trial / NCT04567069
Safety and Efficacy Study for MG-7-DC Vaccine in Gastric Cancer Treatment
Phase 1/2
Unknown
45 enrolled
The Second Hospital of Shandong University
Shandong Sunstem Biotechnology Co.,Ltd. · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
The primary purpose of the study is to determine the safety and efficacy of autologous DC vaccine in patients with later stage of gastric cancer. The DC vaccine is gene modified with gastric cancer specific antigen MG-7.
Timeline
- Start
- 2020-09
- Primary completion
- 2021-12
- Completion
- 2022-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CTL | Cell therapy | 1e+09 cells | Intravenous |
| Subject | CTL | Cell therapy | 2e+09 cells | Intravenous |
| Subject | DC vaccine | Vaccine | 1e+06 cells | Subcutaneous |
| Subject | DC vaccine | Vaccine | 3e+06 cells | Subcutaneous |
| Subject | Sintilimab | Monoclonal antibody | 3 mg/kg | Intravenous |